| Comparing effectiveness and safety of SGLT2 inhibitors vs DPP-4 inhibitors in patients with type 2 diabetes and varying baseline HbA1c levels E D’Andrea, DJ Wexler, SC Kim, JM Paik, E Alt, E Patorno JAMA Internal Medicine 183 (3), 242-254, 2023 | 24 | 2023 |
| The glutathione-S-transferase mu-1 null genotype increases wood smoke-induced airway inflammation AJ Burbank, A Vadlamudi, KH Mills, EM Alt, H Wells, H Zhou, N Alexis, ... Journal of Allergy and Clinical Immunology 143 (6), 2299-2302. e3, 2019 | 14 | 2019 |
| Bayesian multivariate probability of success using historical data with type I error rate control EM Alt, MA Psioda, JG Ibrahim Biostatistics 24 (1), 17-31, 2023 | 6 | 2023 |
| The scale transformed power prior for use with historical data from a different outcome model EM Alt, B Nifong, X Chen, MA Psioda, JG Ibrahim Statistics in medicine 42 (1), 1-14, 2023 | 5 | 2023 |
| LEAP: The latent exchangeability prior for borrowing information from historical data EM Alt, X Chang, X Jiang, Q Liu, M Mo, HA Xia, JG Ibrahim arXiv preprint arXiv:2303.05223, 2023 | 2 | 2023 |
| Discussion of “Optimal test procedures for multiple hypotheses controlling the familywise expected loss” by Willi Maurer, Frank Bretz, and Xiaolei Xun LM LaVange, EM Alt, JG Ibrahim Biometrics 79 (4), 2802-2805, 2023 | 1 | 2023 |
| Risk of severe hypoglycemia with newer second-line glucose-lowering medications in older adults with type 2 diabetes stratified by known indicators of hypoglycemia risk PT Htoo, JM Paik, E Alt, DH Kim, DJ Wexler, SC Kim, E Patorno The Journals of Gerontology: Series A 78 (12), 2426-2434, 2023 | 1 | 2023 |
| A Bayesian approach to study design and analysis with type I error rate control for response variables of mixed types EM Alt, MA Psioda, JG Ibrahim Statistics in Medicine 42 (11), 1722-1740, 2023 | 1 | 2023 |
| Bayesian design of clinical trials using the scale transformed power prior X Chen, B Nifong, EM Alt, MA Psioda, JG Ibrahim Journal of Biopharmaceutical Statistics, 1-20, 2024 | | 2024 |
| Safety signal detection with control of latent factors X Tan, W Wang, D Zeng, GF Liu, G Diao, N Jafari, EM Alt, JG Ibrahim Statistics in Medicine, 2024 | | 2024 |
| Predicting Treatment Effects of a New‐to‐Market Drug in Clinical Practice Based on Phase III Randomized Trial Results HJ Shin, SV Wang, DH Kim, E Alt, M Mahesri, LG Bessette, ... Clinical Pharmacology & Therapeutics 114 (4), 853-861, 2023 | | 2023 |
| MSR40 Predicting Treatment Effects of a New-to-Market Drug in Clinical Practice Based on Phase III Randomized Trial Results H Shin, S Wang, DH Kim, E Alt, M Mahesri, LG Bessette, S Schneeweiss, ... Value in Health 26 (6), S285, 2023 | | 2023 |
| A hierarchical prior for generalized linear models based on predictions for the mean response EM Alt, MA Psioda, JG Ibrahim Biostatistics 23 (4), 1165-1181, 2022 | | 2022 |
| Risk of hypoglycemia with sodium glucose cotransporter-2 inhibitors versus alternative glucose lowering medications in patients with and without baseline use of insulin or … P Htoo, D Wexler, S Kim, J Paik, E Alt, D Kim, E Patorno PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 31, 113-113, 2022 | | 2022 |
| Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors (SGLT2i) versus dipeptidyl peptidase 4 inhibitors (DPP-4i) in T2D patients across different … E D'Andrea, D Wexler, J Paik, E Alt, S Kim, E Patorno PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 31, 331-332, 2022 | | 2022 |
| Bayesian Methods for the Use of Historical Data and Prior Information in Clinical Trials EM Alt The University of North Carolina at Chapel Hill, 2021 | | 2021 |
| Characterizing Airway Inflammatory Responses to Wood-Smoke Inhalation AJ Burbank, ML Hernandez, KH Mills, N Alexis, EM Alt, H Zhou, ... Journal of Allergy and Clinical Immunology 143 (2), AB23, 2019 | | 2019 |
| A Bayesian approach to multiple testing, analysis, and study design for response variables of mixed types EM Alt, MA Psioda, JG Ibrahim | | |
Joseph G. IbrahimUNCVerified email at bios.unc.edu
